Related Experiment Video
Updated: Mar 2, 2026

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
Published on: January 7, 2019
First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario
Sheryl Spithoff1, Suzanne Turner2, Tara Gomes3
1Family physician and addiction physician at Women's College Hospital in Toronto, Ont, and a lecturer at the University of Toronto. sheryl.spithoff@wchospital.ca.
Objective:
To examine use of first-line alcohol use disorder (AUD) medications (naltrexone and acamprosate) among public drug plan beneficiaries in the year following an AUD diagnosis.
Design:
Retrospective population-based cohort study.
Setting:
Ontario.
Participants:
Individuals eligible for public drug plan benefits who had an AUD diagnosis at a hospital visit between April 1, 2011, and March 31, 2012.
Main Outcome Measures:
Number of AUD medications dispensed to public drug plan beneficiaries who had a recent hospital visit with an AUD diagnosis, and number of prescriptions dispensed per person.
Results:
A total of 10 394 Ontarians between 18 and 65 years of age were identified who had a hospital visit with an AUD diagnosis and were eligible for public drug plan benefits. The rate of AUD medications dispensed in the subsequent year was 3.56 per 1000 population (95% CI 2.51 to 4.91; n = 37). This rate did not differ significantly by sex (P = .83).
Conclusion:
Very few public drug plan beneficiaries are dispensed first-line AUD medications in the year following an AUD diagnosis.
More Related Videos
Related Concept Videos
CNS Depressants: Alcohol and Nicotine
Drug Therapy
Antianxiety Medications
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Drug Dependence
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

